Goutham Sunny

@drmpk91 @Arvind_RadOnc @LancetRH_SEAsia @OffCMCVellore @todrashish @ajoyojohn @jtgeorgy @HK_DMonc @DarwinAnil Congratulations!!

Excited to share that our phase 2 trial #NeoLOCUS is now out in @LancetRH_SEAsia! A collective effort from the Head & Neck team @OffCMCVellore led by @todrashish We report R0 rates, ORR, safety, survival outcomes, tumor immune microenvironment change🧵👇 thelancet.com/journals/lanse…

Let's review #TNT Total Neoadjuvant Treatment and Organ Preservation in #Rectal #Cancers. 1. PRODIGE23 - Induction CT + CRT 2. PROSPECT - No RT & Mid/upper only 3. OPRA - Induction CRT CT Ph2 4. OPERA - Contact Brachy Boost 5. MORPHEUS - HDR BT boost #crcsm #Oncology

#fda approvals in 2025 for #lcsm Lung cancer

@leftyindian Congratulations 🥳

I have successfully completed Drnb Medical Oncology at Mvr Cancer center Calicut. 3 years of hardwork perseverance and incredible learnings. Leaving Calicut with a lot of fond memories. Now it's time to go home #medicaloncology

@jtgeorgy @DarwinAnil @todrashish @OffCMCVellore @myESMO @ajoyojohn @ajoel_84 @JenniferSudahar @sanujthomas @UzagareJoshua @ISMPOofficial @IndianYoungOnco @SuyogCancer @ullas_batra Congratulations to the whole team! Very important work @OffCMCVellore

Huge Congratulations to @DarwinAnil @todrashish, MedOnc and Clin Pharm @OffCMCVellore on presenting our phase II #TOCAN trial at @myESMO #ESMOAsia25 Efficacy, PK analysis of thrice weekly #osimertinib + chemo in EGFRm #lungadenocarcinoma. ✨ORR ~90% ☀️18 mo PFS : 78.8% OS: 89.5%

Congratulations to the whole team! Cheers to silver and blue ♥️@OffCMCVellore

🚨 RT + targeted therapy is NOT the same for all drugs This new ESMO-ESTRO consensus finally settles it 👇 🟢 Anti-HER2 (trastuzumab, pertuzumab) → RT usually safe → Minor or no treatment changes 🟠 CDK4/6 inhibitors → Watch the gut → GI and mucosal toxicity signal → Extra caution for abdomen, pelvis, thorax 🔴 PARP inhibitors → Potent radiosensitizers → Even low doses amplify RT toxicity → Major treatment adaptation needed 🟠 mTOR inhibitors → Pneumonitis, mucositis, cytopenias → Avoid high-dose thoracic RT when possible 🧠 Clinical pearl RT + targeted therapy is a timing and biology problem, not a yes or no question. 📖 Full paper in comments ⬇️ 🔖 Save this for tumor boards #OncoTwitter #RadOnc #MedTwitter #TargetedTherapy #BreastCancer @myESMO @ESTRO_RT @esmo_open @OncoAlert

My new paper now out in @JNCI_Now where I make a case for why de-escalation trials can be designed as superiority instead of non-inferiority. This allows for smaller sample size making de-escalation trials faster, cheaper, and more efficient. academic.oup.com/jnci/advance-a… @OncologyBGLab

DLBCL treatment has gotten more complicated Back in my day it was RCHOP if relapse salvage and ASCT

Rechallenge benefit score New data from a 16-center French study shows that routine inflammation-based biomarkers can help identify which NSCLC patients may benefit from ICI rechallenge. The Rechallenge Benefit Score (RBS) outperforms clinical features, stratifies rPFS effectively (6.4 vs 1.9 months), and is specific to the rechallenge setting. A practical tool to refine post-ICI decision-making. #precisiononcology #lcsm doi.org/10.1016/j.ejca…

Phase 2 KANNON shows that andamertinib 240 mg daily delivers meaningful activity in previously treated EGFR exon20 insertion–mutant NSCLC. ORR 42.7%, disease control 86.5%, median DOR 8.7 months, and encouraging CNS activity with ORR 47.4% in patients with brain metastases. Toxicities were manageable with no ILD or grade ≥3 QT prolongation. A promising option for this difficult-to-treat subset. doi.org/10.1016/j.jtho… #lcsm

@jtgeorgy @UniofOxford @OxfordOncology @OffCMCVellore @todrashish @adj_23 @ajoyojohn @drkevinjj @jayastuMD @akhilrk1989 @drmpk91 @DarwinAnil @DrZachariahT @Harikri44884728 @JenniferSudahar Congratulations Josh!! Well deserved. There will be many more such accolades to come. @OffCMCVellore is truly blessed to have you!

Thrilled to share I’ve started the MSc Precision Cancer Medicine at @UniofOxford @OxfordOncology on a Clarendon Scholarship. Aiming to advance cancer care for our patients @OffCMCVellore, tackle imp research questions. Gratitude to my mentors @todrashish @adj_23 Nithya Ramnath🙏

If you look at it as just filling forms as a spinal level work and don’t think beyond it then it’s pretty pointless. We would work with residents in the ward and learn why a form is being filled for an investigation and then follow up the results and learn its interpretation. The best learning happens at the bedside from the patient. It’s all about how you approach the job that’s assigned to you. You might mug up a fact for 10 hours but once you’ve a co-managed or have that clinical correlation, it doesn’t take more than 10 mins the first time you read it. Yes, all this is not applicable if you’re in a college without actual patients and you’re filling up pages of fake reports and tests of imaginary patients. Also you’ll need good residents who are confident themselves and eager to teach and learn themselves.

@Geeky_Foodie Form bharne mai konsa instant gratification? Isme kaunsa purpose dikhta hai? 😭😭😭

I still don't understand what some interns get by being super sincere????

🐘 The elephant in the room: we don’t know how to sequence all these TOPO1 ADCs.

@foxpaws_onco @DrYukselUrun Me too

@DrYukselUrun 🤔 oh dear, i read it as prostate coffee

Caffeine and early detection both save mornings! Ask your barista if regular screening is right for you ☕️

Options for HER2-positive breast cancer are increasing🚀🎉 It was announced that maintenance tucatinib combined with HP after THP provides a significant PFS advantage (HER2CLIMB-05) Now we have 3 new options. Minds are confused. Data mining awaits us🤯

INTERLACE or KEYNOTE-A18 for #CervicalCancer ? 🤔 It’s all about patient selection, risk profile, safety and clinical context💡 @OncoAlert

So proud of @jtgeorgy and the whole team at @OffCMCVellore for doing such an impactful and relevant study for India and all LMICs. Truly amazing work 🫡

Happy to share our experience... What immunotherapy can achieve in advanced non metastatic HNSCC ? hope this will help our patients in india.. 🇮🇳 @ICMRDELHI @csoncol nature.com/articles/s4159…